Michael Grever

The Ohio State University as a Lead Academic Organization (LAO) for the Experimental Therapeutics Clinical Trials Network

National Cancer Institute · UM1

Contact PI · $3.8M · Ohio State University

Chronic Lymphocytic Leukemia Research Consortium

National Cancer Institute · P01

Project lead · $2.5M · University of California, San Diego

Experimental Therapeutics of Leukemia

National Cancer Institute · P50

Project lead · $1.3M · Ohio State University

Phase I Trials of Anti-Cancer Agents

National Cancer Institute · U01

Contact PI · $9.4M · Ohio State University

Hairy Cell Leukemia Patient Data Registry

Principal investigator · Recruiting

Ohio State University Comprehensive Cancer Center

Temsirolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma

Principal investigator · Completed · Phase 2

National Cancer Institute (NCI)

Fludarabine With or Without Cyclophosphamide in Treating Patients With Chronic Lymphocytic Leukemia

Study chair · Completed · Phase 3

Eastern Cooperative Oncology Group

A Study of Vemurafenib and Obinutuzumab Compared to Cladribine and Rituximab in People With Hairy Cell Leukemia (HCL)

Site PI · Recruiting · Phase 2

Memorial Sloan Kettering Cancer Center